Sound familiar? China/US biotech hybrid lands rights to cancer drugs, cash and a team of development vets to launch Oncologie

Another transpacific biotech has launched with the backing of an emerging group of venture investors in China as well as a plan to build a pipeline of cancer drugs that can be swiftly developed for the booming Asian market.